CTRI/2018/09/015810已完成3 期
“A Phase III, Multicenter, Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis.â€
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 236
- 试验地点
- 16
- 主要终点
- Change in ocular itching score from baseline at all visits after randomization
研究概览
简要总结
This is A Phase III, Multicenter, Comparative, Randomized, Double blind, Two arm, Parallel group Clinical Study to evaluate Efficacy and Safety of Fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis.
Primary Objective: To evaluate the efficacy of fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis.
Secondary Objective: To evaluate the safety of fixed dose combination of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops compared with Alcaftadine Ophthalmic Solution 0.25% w/v for the treatment of Subjects with Ocular Itching associated with Allergic Conjunctivitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Participant and Investigator Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Male or female subjects, aged 18 years to 65 years (both inclusive).
- •2.Treatment naïve subjects with diagnosis of ocular itching associated with allergic conjunctivitis (primary outcome measure).
- •4.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
排除标准
- •1.Subjects with Giant Papillary Conjunctivitis (GPC) will be excluded from the study.
- •2.Subjects with Presence of active blepharitis, active meibomian gland dysfunction, active rosacea affecting the ocular adnexa, follicular conjunctivitis, iritis, preauricular lymphadenopathy, ocular irritation not due to ocular allergy, or any other clinically significant ophthalmic abnormality that may affect the study outcomes 3.Subjects with presence of ocular infection (bacterial, viral or fungal) or history of ocular herpes within 3 months of screening visit.
- •4.Subjects with chronic ocular degenerative condition or active intraocular inflammation that could worsen during the study.
- •5.Subjects with known case of persistent dry eye syndrome or currently on treatment for dry eyes.
- •6.Subjects with known case of corneal epithelial detachment, corneal ulcer, Keratitis and evidence of corneal epithelial breakdown etc.
- •7.Subjects with known case of glaucoma will be excluded from the study.
- •9.Subjects planned to use contact lenses in the study eye during the study period.
- •10.Subjects with Visual acuity of 20/80 in any eye.
- •11.Subjects with Type 1 diabetes or Type 2 diabetes mellitus with HbA1c value greater than 8% within last 3 month prior to screening will be excluded from the study.
- •12.Subjects with known case of diabetic retinopathy.
- •13.Subjects with known case of clinically significant trauma to the study eye within the past 12 months.
- •14.Subjects who are blind or subjects with single eye will be excluded from the study.
- •15.Subjects with active peptic ulcer disease, gastrointestinal bleeding or perforation, or known history of peptic ulcer disease or gastrointestinal bleeding or any other bleeding disorders.
- •16.Clinically relevant recent (within 6 months of baseline visit) history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, autoimmune disease and other relevant systemic diseases that would preclude the safe administration of the Investigational product.
- •17.Subjects with 1 month prior to screening visit or current use of systemic, topical or ocular corticosteroids, NSAIDs, anticholinergics, immunosuppressants, or H1-antihistamines.
- •18.Any contraindications or hypersensitivities to the use of the study medication or their components.
- •19.History of alcohol abuse and smoking.
- •Females who are not ready to use acceptable contraceptive methods during the course of study.
- •21.Concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
- •22.Suspected inability or unwillingness to comply with the study procedures.
结局指标
主要结局
Change in ocular itching score from baseline at all visits after randomization
时间窗: At the end of Day 28
次要结局
- Change in conjunctival hyperemia grade from baseline at all visits after randomization.(Change in Tearing score from baseline at all visits after randomization.)
研究者
研究点 (16)
Loading locations...
相似试验
尚未招募
3 期
A Phase Ⅲ Comparative Study of QL2108 to Dupixent®Atopic DermatitisNCT06884891Qilu Pharmaceutical Co., Ltd.520
招募中
3 期
A study of Alfuzosin and Tadalafil Combination Tablets in treatment of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH).CTRI/2022/06/043443Akums Drugs Pharmaceuticals Limited270
已完成
3 期
A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung CancerNon-squamous Non-small Cell Lung CancerNCT03329911Bio-Thera Solutions651
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Dapagliflozin and Sitagliptin phosphate tablets in comparison to Sitagliptin phosphate tablets as an additional treatment to Metformin tablets in patients with type 2 diabetesCTRI/2021/06/033962Sun Pharma Laboratories Limited378
已完成
3 期
Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute UrticariaAcute UrticariaNCT02935699JDP Therapeutics, Inc.262